VectorY presents new pre-clinical data at the European Network for the Cure of ALS (ENCALS)
‘VecTabs’ developed using VectorY’s proprietary platform show positive effect on key drivers of ALS pathology AMSTERDAM–(BUSINESS WIRE)–VectorY, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of neurodegenerative and muscular disorders through vectorized antibodies, today announced new data at the 2022 ENCALS meeting in Edinburgh. The poster, which was … [Read more…]